New Partnership Forged To Research Marijuana As A Treatment For Autism

cannabis science

Cannabis Science Reaches Final Partnership Structure with Unconventional Foundation for Autism (UF4A)

Cannabis Science, Inc. , a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce clarification and partnership structure with The Unconventional Foundation for Autism ("UF4A").

Cannabis Science wishes to clarify that the partnership is only a partnership with UF4A. Cannabis Science has no relationship or affiliation with the University of California, Irvine, the Dean of the UCI School of Medicine, or any of its faculty ("UCI"). UF4A has no affiliation with UC Irvine, though UC Irvine psychiatrist Dr. Rebecca Hedrick treats the autistic son of UF4A founder, Mieko Hester-Perez. Neither UCI nor Dr. Hedrick is conducting research into medical marijuana and autism. After exhausting all traditional medical options and with Hester-Perez's son's life in question, Hester-Perez chose to augment her son's therapy with cannabis under a state compliant recommendation. As a result, her son saw marked improvement and was able to eliminate approximately 80% of the prescription drugs from his daily regimen.

The partnership structure between Cannabis Science and UF4A will focus on the advancement of medical marijuana to treat autism patients, and to build acceptance for this natural and remarkably effective autism treatment. The partnership promises to bring innovative autism research and to help raise awareness among traditional medical professionals that remain unaware of the drug's benefits and low toxicity profile.

Dr. Robert Melamede Ph.D., Cannabis Science Inc., President & CEO, stated, "We are excited to continue the partnership with UF4A and help advocate for the treatment of Autism with medical marijuana, in addition to our launch party and other public forums and media initiatives. Autism stands out amongst medical conditions because there is no medicine to treat it, and the only relating medicine are prescribed for the associated side effects and not Autism itself. Medical marijuana is the only medicine that can directly treat the Autism and without the horrific side effects of pharmaceuticals."

Hester-Perez attributes dramatic improvements in her son's behavior and overall health to the addition of cannabis to his treatment. Approximately 10 other autistic persons have seen improvements since augmenting their therapy with cannabis within UF4A's case studies. She hopes this will form the basis for official academic research in the future.

A partnership launch party is currently being planned to help roll out our public awareness campaign and goals for advancing acceptable medical marijuana therapy for autism patients.

Medical Leaf

About UF4A

The Unconventional Foundation for Autism, UF4A for short, is a non-profit organization. The mission of UF4A is three fold: (1) to raise awareness and support for families afflicted with this mysterious and misunderstood condition known as Autism; (2) to raise funds for cannabis-based medical research and clinical trials; and (3) to campaign for a rescheduling of cannabis from Schedule 1 narcotic (no accepted medical benefits) to a lower schedule so that the appropriate research may be conducted, and so that all patients have access to medication. A listing on Schedule 1 is tantamount to a research blockade and, frankly, is unacceptable where millions continue to needlessly suffer and subject to criminal punishment should they choose to use cannabis under the direction of their physician. The Schedule 1 listing fails to reflect the prevailing medical view that cannabis has accepted medical benefits. UF4A is quickly becoming a leading advocate in the fight for nationwide investigation, research and analysis of the legalization of Medical Marijuana.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.